Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 54, pages 635–640 (2019)Cite this article

Subjects

Letter to the Editor,

Allogeneic stem cell transplantation (alloSCT) leads to an increased risk of secondary malignancies (SM), because of patients exposure to chemotherapy (CT), radiotherapy (RT), GVHD, and immunosuppressive therapy [1,2,3,4,5]. Information regarding exact dosages of these exposures are lacking. This retrospective single center cohort study of 1 169 adult patients who received 1st alloSCT between 1986 and 2014 explored the effect of individual per patient CT-dosages and RT-dosages on SM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Majhail NS. Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol. 2011;154:301–10.

    Article  Google Scholar 

  2. Soci G, Baker KS, Bhatia S. Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:S139–50.

    Article  Google Scholar 

  3. Rizzo JD, Curtis RE, Sobocinski KA, Gilbert E, Landgren O, Travis LB, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2016;113:1175–84.

    Article  Google Scholar 

  4. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316–22.

    Article  CAS  Google Scholar 

  5. Travis LB, Curtis HE, Glimelius B, Eric J, Van LeeuwenFE, Lynch CF, et al. Bladder and Kidney cancer following cyclophosphamide therapy for Non-Hodgkin’ s lymphoma. J Natl Cancer Inst. 1995;87:524–30.

    Article  CAS  Google Scholar 

  6. Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18:348–57.

    Article  Google Scholar 

  7. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904.

    Article  CAS  Google Scholar 

  8. Bhatia BS, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’ s disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–94.

    Article  Google Scholar 

  9. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB, Stevens MCG. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer. 2004;91:1905–10.

    Article  CAS  Google Scholar 

  10. Oeffinger KC, Baxi SS, Novetsky Friedman D, Moskowitz CS. Solid tumor second primary neoplasms: who is at risk, what can we do? Semin Oncol. 2013;40:676–89.

    Article  Google Scholar 

  11. Baker BKS, Defor TE, Burns LJ, Ramsay NKC, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors conclusion. J Clin Oncol. 2003;21:1352–8.

    Article  Google Scholar 

  12. Mawardi H, Elad S, Correa ME, Stevenson K, Woo S-B, Almazrooa S, et al. Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011;46:884–91.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Harald Schrem, Christian Koenecke

Authors and Affiliations

  1. Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover Medical School, Hannover, Germany

    Anke Katrin Ziegler, Elke Dammann, Matthias Eder, Arnold Ganser & Christian Koenecke

  2. Core Facility Quality Management Transplantation, Integrated Research and Treatment Center Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany

    Anke Katrin Ziegler, Rieke-Sophie Homeyer & Harald Schrem

  3. Bundeswehr Institute of Radiobiology, Munich, Germany

    Anke Katrin Ziegler, Michael Abend & Matthias Port

Authors
  1. Anke Katrin Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Abend
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Port
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke Dammann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rieke-Sophie Homeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matthias Eder
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arnold Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Harald Schrem
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christian Koenecke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Koenecke.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical considerations

The study was conducted according to the declaration of Helsinki and approved by the local ethics committee of Hannover Medical School (Approval Number: 2375–2014).

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ziegler, A.K., Abend, M., Port, M. et al. Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 54, 635–640 (2019). https://doi.org/10.1038/s41409-018-0359-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0359-2

Search

Advanced search

Quick links